Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 4/20 | 0.48 |
| ▸ | F10 | P00742 | 6/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | PPIA | P62937 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3560576 | 1.00 | CCKBR (0.48) | CCKBRF10UTS2RBCHEMEN1 | |
| SCHEMBL3559100 | 1.00 | CCKBR (0.48) | CCKBRF10UTS2RBCHEMEN1 | |
| SCHEMBL3566371 | 0.87 | FPR2 (0.45) | F10UTS2REP300 | |
| SCHEMBL3567334 | 0.86 | UTS2R (0.43) | CCKBRF10UTS2RMAPTEP300 | |
| SCHEMBL3562613 | 0.86 | F10 (0.46) | CCKBRF10UTS2RMEN1MAPT | |
| SCHEMBL3567021 | 0.86 | F10 (0.46) | CCKBRF10UTS2RMEN1MAPT | |
| SCHEMBL3562133 | 0.86 | F10 (0.46) | CCKBRF10UTS2RMEN1MAPT | |
| SCHEMBL3569445 | 0.86 | MEN1 (0.41) | CCKBRF10UTS2RMEN1MAPT | |
| SCHEMBL3563910 | 0.83 | F10 (0.45) | CCKBRF10UTS2RMEN1MAPT | |
| SCHEMBL3557895 | 0.83 | F10 (0.44) | CCKBRF10UTS2RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006063113-A2 | UREAS AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160821-A1 | Ureas as factor Xa inhibitors | TFPI, F12, F11 | CCKBR 1599/4885F10 9/4885UTS2R 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.